Elicio Therapeutics, Inc.
ELTX
Rank in Stocks
#23275
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
Share Price
$1.59
Last synced: 2026-11-18
Market Cap
$41.80M
Change (1 day)
11.19%
Change (1 year)
-80.10%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Elicio Therapeutics, Inc. (ELTX)
Category
Healthcare
EPS for Elicio Therapeutics, Inc. (ELTX)
EPS as of September 2026 TTM: $-1.83
According to Elicio Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.83. At the end of 2025 the company had an EPS of $-2.58, an increase over its 2024 EPS of $-4.25.
EPS history for Elicio Therapeutics, Inc. from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.83 | -29.07% |
| 2025 | $-2.58 | -39.29% |
| 2024 | $-4.25 | -38.94% |
| 2023 | $-6.96 | -23.52% |
| 2022 | $-9.10 | -52.90% |
| 2021 | $-19.32 | 901.04% |
| 2020 | $-1.93 | 28.67% |
| 2019 | $-1.50 | -77.91% |
| 2018 | $-6.79 | -106.57% |
| 2013 | $103.31 | 105.76% |
| 2012 | $50.21 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | -51.37% |
US
|
|
| $15.66 | -955.74% |
US
|
|
| $-7.07 | 286.34% |
US
|
|
| $-5.29 | 189.07% |
AU
|
|
| $12.73 | -795.75% |
BE
|
Questions about Elicio Therapeutics, Inc.'s earnings per share (EPS)
What is Elicio Therapeutics, Inc.'s earnings per share (EPS)?
Elicio Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.83, as of Sep 2026.
What was Elicio Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Elicio Therapeutics, Inc.'s earnings per share (EPS) was $-2.58, compared with $-4.25 in 2024.
How has Elicio Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Elicio Therapeutics, Inc.'s earnings per share (EPS) was highest in 2020 ($-1.93) and lowest in 2021 ($-19.32).
How does Elicio Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Elicio Therapeutics, Inc.'s earnings per share (EPS) ($-1.83) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.